

**PROTEIN ENGINEERING WITH COMPUTATIONAL  
MODELING**

**DISSERTATION**

Submitted in Partial Fulfillment of  
the Requirements for  
the Degree of

**DOCTOR OF PHILOSOPHY (Materials Chemistry)**

at the

**NEW YORK UNIVERSITY  
POLYTECHNIC SCHOOL OF ENGINEERING**

by

**Ching-Yao Yang**

May 2015

Approved:

---

Department Head Signature

---

Date

Copy No. \_\_\_\_

Univerity ID#: N14332422

Approved by the Guidance Committee:

---

**Professor Jin Ryoun Kim**

Associate Professor of Chemical Engineering  
New York University

---

Date

---

**Professor Jin Kim Montclare**

Associate Professor of Chemistry  
New York University

---

Date

---

**Professor Rastislav Levicky**

Associate Professor of Chemical Engineering  
New York University

---

Date

---

**Professor Stacy Blain**

Associate Professor of Molecular Biology  
SUNY Downstate Medical School

---

Date

---

**Professor Raymond Tu**

Associate Professor of Chemical Engineering  
City College of New York

---

Date

Microfilm or copies of this dissertation may be obtained from:

UMI Dissertation Publishing  
ProQuest USA  
789 E. Eisenhower Parkway  
P.O. Box 1346  
Ann Arbor, MI 48106-1346

## Vita

Carlo Yuvienco was born in New York, New York on March 22<sup>nd</sup>, 1983 to Dr. Francisco P. Yuvienco and Elizabeth T. Yuvienco. His academic and professional pursuits would reside in New York until the time of this work, starting with his secondary education at Stuyvesant High School. This was followed by an undergraduate education in chemical engineering at the Cooper Union for the Advancement of Science and Art, culminating in a Bachelor of Engineering (granted in 2005). Carlo then was employed at Pall Corporation (East Hills, NY) as a research scientist, working on the development of leukocyte-reduction filtration media. After two years of industry experience, Carlo pursued a Master of Science in biomedical engineering at the Polytechnic Institute of New York University (granted in 2010), immediately preceding the pursuit of his doctorate in biomedical engineering under the advisement of Prof. Jin Kim Montclare, Ph.D. at the now New York University - Polytechnic School of Engineering, in the Department of Chemical and Biomolecular Engineering. From 2008 to 2014, Carlo worked on several projects in the field of protein engineering under the guidance of Prof. Montclare, having conducted experiments in various labs within New York University, the Navy Research Laboratory, the Wright-Patterson Air Force Base Materials and Manufacturing Directorate, and the City University of New York. During the course of his doctoral research, he and his research projects have been supported by the National Science Foundation (GK-12 Program, DGE-0741714; NYU MRSEC Center, DMR-0820341; I-Corps Program, IIP-1332165; DMR-1205384), the Air Force Office of Scientific Research (FA-9550-07-1-0060 and FA-9550-08-1-0266), and the Army Research Office (W911NP-10-1-0228).

# Acknowledgments

This body of work encompasses seven years of effort that would not have been possible without the professional and emotional support of my friends, family, and newfound colleagues. I declare my immense thanks to them for the following reasons.

First, to my family:

The continuous pride and understanding that my family has expressed in regards to the pursuit of my doctorate has been the driving force behind my stalwart efforts these past few years. They have continued to champion my marathon despite my long-awaited presence at the finish line. And during the times of despair and frustration that commonly plague scientific research, I have always been able to benefit from the respite that I received in the sanctuaries that were their homes. To all of them, I convey my eternal gratitude and love.

To my colleague, friend, and mentor - Jin Montclare:

From day one, you have continued to foster and promote my advancement as a scientist and intellectual. Assuredly, I am a better person for it. We have celebrated academic successes as well as suffered scientific and professional tribulations. But perhaps most importantly, regardless of the context, you have undoubtedly and consistently demonstrated your utmost trust in both my abilities and my character - a privilege for which I can only hope I have abundantly reciprocated in kind. Thank you very much for the momentous opportunity to have worked with you.

To my colleagues:

There are many individuals to whom I owe thanks for their professional support during the course of my doctoral studies. They include fellow students (high school, undergraduate, and graduate alike), accomplished scientists, aspiring professors, and university administrators and staff. A vast majority of them have provided me with an infinitely expansive sounding board for my ideas and have in turn stimulated the

advancement of my research. Others have quelled quagmires before they escalated toward affecting the completion of my degree. And others have simply promoted my advancement as a research scientist through the extension of rare professional opportunities.

To my close friends:

I submit my sincerest apologies, more so and in addition to my gratitude. A graduate career of seven years has in truth robbed me of many occasions to spend with my close personal friends. They have nevertheless continued to support my pursuit and take pride in my endeavors.

And to my Jennifer:

Without an iota of doubt, my professional accomplishments would not have been possible without the love and support that you have devoted to me. You have kept me company during late night experiments. You have consoled me during times of struggle and sadness. You have cheered my successes and announced them atop mountains. You are my rock and my cushion. And in my seven-year pursuit of knowledge of the unknown, I have come to only one surety - that I love you.

To all of you again - thank you.

**ABSTRACT**  
**PROTEIN ENGINEERING WITH COMPUTATIONAL MODELING**

by

**Ching-Yao Yang**

**Advisor: Prof. Jin Kim Montclare, Ph.D.**

**Submitted in Partial Fulfillment of the Requirements for  
the Degree of Doctor of Philosophy (Materials Chemistry)**

**May 2015**

With the advancement of technologies to probe and manipulate biophysical matter, the scientific community continues to ever better engineer biological systems with the complexity and elegance in design that is necessary to address biomedical challenges. The growing maturity of the field of protein engineering is a testament to this proclamation. Herein, two fundamental ideas are explored. In Chapter I, an evaluation is presented on the effects of the incorporation of a non-canonical, fluorinated amino acid into a protein-based block copolymer. The ramifications of these results, and similar others in the field, on the promise for predictable tuning of the physicochemical behavior and properties of protein-based materials are emphasized. In Chapter II, an alternative application of an endogenous protein is examined, harnessing its inherent form and function. Hypotheses postulate the ability of a coiled-coil protein, of particularly high oligomeric order, to facilitate the delivery of small molecule therapeutics for the treatment of osteoarthritis, whilst addressing dominant hurdles pertaining to drug localization. This complete body of work rests on the themes of control and repurposed application of biophysical matter, contributing to the formalization of engineered systems within protein science.

# Chapter 1

## Improved Stability and Half-Life of Fluorinated Phosphotriesterase Using Rosetta

### 1.1 Introduction

#### 1.1.1 Rosetta and Protein Engineering

Computational tools are widely used for protein engineering [ref]. Rosetta suite was first developed in University of Washington [ref]. Baker et al. adapted this suite for prediction of three: dimensional structure of proteins. This suite provides a handful of protocols for analyzing and mutating protein structures. The simulation relies heavily on knowledge-based potentials. It is a suite of libraries and tools for macromolecular ligand docking, to thermo-stabilize proteins, to design a hydrogen-bond network, to design novel protein folds, to create novel protein interfaces, and to design enzymes, including some containing unnatural amino acids in the active sites.



### 1.1.2 Phosphotriesterase

PTE is a homodimeric protein composed of two monomers, each of which contains a metallo-active site. Phosphotriesterase (PTE) are enzymes, which hydrolyze organophosphates (OPs) as well as synthetic esters.[1] OPs are a synthetic class of small molecule that irreversibly inactivate acetylcholinesterase (AChE), disrupting neural transmission. AChE is an enzyme that degrades the neurotransmitter, acetylcholine, at the neuromuscular junction in the cholinergic nervous system. After the acetylcholine is hydrolyzed, the synaptic transmission would be terminated. Inhibition of AChE lead to hyper-stimulation from toxic accumulation of acetylcholine.[2] Army also adapted this protein for chemical weapons neutralization. [3]

### 1.1.3 Incorporation of non-natural amino acids

Several methods have been developed for the incorporation of unnatural amino acids into proteins: solid-phase synthesis (SPPS)[4], in vivo and in vitro site-specific incorporation, 16 and residue-specific incorporation (Fig. 1)1d, 17. In SPPS, activated amino acids are immobilized on a solid support and synthesized step-by-step in the reactant solution. This method is convenient for the introduction of functional groups into peptides, but it is still restricted to the yield and the expense of peptides. For example, if each coupling step has 99% yield, a 26-amino acid peptide would be synthesized in 77% final yield. To synthesis longer chain peptides and proteins bearing UAAs, biosynthetic methods have been developed. There exists two contemporary methods to biosynthetically incorporate non-natural amino acids into proteins: site-specific incorporation and residue-specific incorporation. Schultz and their coworkers<sup>18</sup> have developed a general approach for the in vitro synthesis of proteins. The approach relies on the suppression of an amber termination codon (UAG) in the mRNA by an amber suppressor tRNA charged with the amino acid analog. This

method has been well studied and developed in research of protein structures and functions<sup>19</sup>.

Methods to incorporate amino acid analogues site-specifically into proteins in vivo greatly expand research of unnatural amino acids. We are not only able to synthesize large amounts of protein, but capable of overcoming potential problems including post translational modifications. An in vivo site-specific method to incorporation UAAs was developed by Schultz and coworkers<sup>21</sup>. A stop codon at the position of interest is encoded in the mRNA. For in vivo site-specific UAA incorporation, an orthogonal aminoacyl-tRNA synthetase charges an orthogonal tRNA with particular UAA, and the suppressor tRNA would help the incorporation of UAA with recognition of a stop codon. As cells contain 20 aminoacyl-tRNA synthetase/suppressor tRNA pairs, a new one is required for the incorporation. An orthogonal aminoacyl-tRNA synthetase/suppressor tRNA pair based on a TyrRS/tRNA<sup>Tyr</sup> pair in the *Methanococcus jannaschii* has been engineered for use in *E. coli* for the incorporation of tyrosine analogs<sup>21a</sup>.

As an alternative to site-specific incorporation, residue-specific incorporation has been developed in which a natural amino acid is replaced with an UAA. Auxotrophic strains or organisms that cannot biosynthesize a particular natural amino acid, has been used to introduce multiple UAAs throughout the protein sequence. UAAs that are isosteric to natural amino acids are capable of being recognized by the natural aminoacyl-tRNA synthetase (aaRS), charging the appropriate tRNA enabling the introduction of UAA into the protein sequence without alteration of the biosynthetic machinery. However, to introduce UAAs with gross differences from the natural amino acids, further engineering of the aaRS is required. To incorporate refractory methionine analogs, Tirrell and coworkers engineered additional copied of the methionyl-tRNA synthetase (MetRS) by adding the MetRS gene under constitutive promotor<sup>22</sup>. Alternatively, Schimmel and coworkers mutated editing pocket of valyl-

tRNA synthetase (ValRS) to facilitate the incorporation of analogs that normally would not be accepted by endogenous aaRS<sup>23</sup>. Finally, Kast and coworkers generated a mutated phenylalanyl-tRNA synthetase (PheRS), ePheRS\* under a constitutive promoter, with a large binding pocket (T251G) and showed relaxed specificity.<sup>24</sup>

### 1.1.4 Fluorinated amino acids in proteins

Fluorinated amino acids (FAAs), represent a unique class of UAAs. They have different bond energies, electron distributions, and hydrophobicity<sup>26</sup> as compared to their hydrogenated counterparts. As we compare the structure of fluorocarbon groups, the C-F bond is highly dipolar while the hydrocarbon is less. The C-F bond is roughly 0.24 longer than C-H bond<sup>26</sup> (Table 1). While in some cases the global replacement of hydrophobic amino acids with fluorinated analogs has led to the stabilization of protein structure<sup>27</sup>, it has all been shown that in some cases they can reduce the thermodynamic stability<sup>28</sup>.

### 1.1.5 Scope of work

The primary goals of this work were to adapt Rosetta for phosphotriesterase. Overall, with incorporation of *pFF* into protein, we will be able to evaluate the performance of scoring function. In advance, we would evaluate the shelf life and thermostability of phosphotriesterase.

## 1.2 Methods

### 1.2.1 General

All chemicals, reagents, and substrate were purchased from Sigma. T4 DNA ligase was purchased from Roche. DNA sequence was confirmed by Eurofins MWG Operon.

96-well plates were purchased from Thermo Fisher Scientific (Waltham, MA).

### 1.2.2 Recombinant gene construction

pQE30-S5 was used as described before. The pQE30-104A plasmid was prepared with forward primers (5-GATGTGTCGACTGCCGATATCGGTCG-3, Fisher Scientific), reverse primers (5-CGACCGATATCGGCAGTCGACACA-3, Fisher Scientific). The PCR parameters were set as follow for 18 cycles: initial denaturation in 95 °C for 30 seconds, sequential denaturation in 95 °C for 30 seconds, annealing in 55 °C for 1 minute, and extension in 68 °C for 4 minutes. The mixture was then incubated 37 °C overnight with DpnI to digest methylated parent DNA strands, which lack the desired mutation. DNA sequence was further confirmed by Eurofins MWG Operon.

### 1.2.3 Protein Expression

Mutant and wild type plasmids were transformed into *E. coli* phenylalanine auxotrophic strains (AF-IQ cells).[5] Electroporation was done at 25 F, 100 Ohms, 2.5 kV (Biorad Gene Pulser II). Cells were plated on agar plates containing 200 g/mL ampicillin, 34 g/mL chloramphenicol. A Single colony was picked and grown in medium (M9 medium supplemented with 0.2 wt % glucose, 35 mg/L thiamine, 1mM MgSO<sub>4</sub>, 0.1mM CaCl<sub>2</sub>, 200 g/mL ampicillin, and 34 g/mL chloramphenicol) with 20 mg/L of 20 amino acids at 37 C, 300 r.p.m. Afterwards, 250 mL of M9 medium for large-scale expression was inoculated 1:50 with an overnight culture. After optical density reached 1.0 at 600 nm, media shift was carried out by washing the cells three times with 0.9% 4 °C  $\text{CaCl}_2$  NaCl. Cells were then transferred to M9 minimal medium containing either 20 amino acids or 19 amino acids (-Phe). pFF-PTE and pFF-104A expression media were supplemented with and 3 mM of pFF and 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) to induce protein expression. 1mM of CoCl<sub>2</sub> was added in each post-induction medium. After three hours incubation at 37 C,

300 r.p.m., the cells were harvested and then resuspended with 20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole, 10% glycerol (pH 8.0) and  $1 \mu\text{mol} \cdot \text{L}^{-1}$  CoCl<sub>2</sub>. Cell lysate was sonicated on ice for 1.5 minutes and then a clarification spin was performed (20,000 g, 4 °C, 30 min). Clarified supernatants were loaded into a His Trap column (G.E Healthcare, Piscataway, NJ) using KTA FPLC purifier (G.E. Healthcare, Piscataway, NJ). Protein elution was generated using elution buffer B (20 mM Tris-HCl, 500 mM sodium chloride, 500 mM imidazole (pH 8.0)). The purified samples were then transferred for buffer exchange using 3X 4L 20 mM phosphate buffer (pH 8.0). Dialyzed protein was subjected to kinetic assays immediately.

### 1.2.4 Thermo-stability and secondary structure of phosphotriesterase

#### 1.2.4a Nano-DSC

DSC (Nano-DSC, TA instrument, USA) was performed by using 600 L (0.1 mg/mL) of protein right after dialysis. Measurements were conducted at a scan rate of 1°C/min. Signals were blanked with buffer under the same condition. The observed diagram was then analyzed by using NanoAnalyze software.

#### 1.2.4b Circular dichroism

CD spectra were recorded on a JASCO J-815 Spectropolarimeter (Easton, MD) using Spectra Manager software. Temperature was controlled using a Fisher Isotemp Model 3016S water bath. Proteins concentrations were 10 M in 20 mM phosphate buffer (pH 8.0). 20 mM phosphate buffer was used for blanking signals. To calculate ellipticities, the following formula was used:

$$\text{mrw} = \text{MRW}(\text{obs}) / (10 * c * l)$$
 where *MRW* is the mean residue weight of the specific phosphotriesterase, *obs* is the observed ellipticities (mdeg), *l* is the path

length (cm),  $c$  is the concentration in M. Spectra was recorded from 190 nm to 250 nm with a scan speed of 1 nm/min.

### 1.2.5 Enzyme Kinetics

The protein was diluted to a final concentration of 30 nM in 20 mM sodium phosphate (pH 8.0) by using the extinction coefficient  $29,280 \text{ M}^{-1} \text{ cm}^{-1}$ . Reactions were monitored spectrophotometrically (Synergy H1, Bio-Tek, Winooski VT) at 405 nm for paraoxon (coefficient =  $17,000 \text{ M}^{-1} \text{ cm}^{-1}$ ). Reactions for paraoxon ( $13 - 104 \text{ M}$ ) was done in 0.4% methanol.  $K_M$  and  $k_{cat}$  values were determined by a Lineweaver-Burk plot ( $1/v$  vs  $1/[S]$ ). [5] The equation used is shown below:

$$1/v = (K_M / V_{Max}) \cdot (1/[S]) + 1/V_{Max}$$

where  $[S]$  represents substrate concentration;  $K_M$  represents the substrate concentration at which the reaction rate is half of  $V_{max}$ . The data reported is the average of three trials and the error represents the standard deviation of those trials.

## 1.3 Results

### 1.3.1 Biosynthesis of phosphotriesterase

The *pFF-F104A* variant and the *pFF-PTE* parent were biosynthesized by residue-specific incorporation with the phenylalanine auxotrophic *Escherichia coli* strain AFIQ.[6] As controls, the non-fluorinated counterparts, PTE and F104A, were expressed under conventional conditions. As expected, all four proteins exhibited good expression in the presence of phenylalanine or *pFF*. *pFF-F104A* and *pFF-PTE* exhibited 80 and 92% incorporation, respectively, as determined by MALDI-TOF mass spectrometry. Notably, purified yields of *pFF-F104A* were twofold higher than for *pFF-PTE*, thus indicating more soluble protein yield.

## 1.4 Discussion

Circular dichroism (CD) was performed to determine whether the mutation had an impact on the overall secondary structure and stability. Far-UV wavelength scans of *p*FF-F104A and *p*FF-PTE showed a double minimum at 208 and 222 nm (25 °C), as expected for a (beta/alpha)<sub>8</sub>-barrel protein, thus suggesting that the mutation did not affect the overall structure (Figure S3). Surprisingly, comparison of the non-fluorinated counterparts revealed that F104A was less structured than PTE (Figure S3). To assess the stability, differential scanning calorimetry (DSC) was performed (Figure 2). Upon heating the sample from 0 to 70°C, *p*FF-PTE exhibited two transitions ( $T_{m1}$ : 42.0 ± 0.1;  $T_{m2}$ : 48.6 ± 0.2 ; Table S1); this is consistent with our previous studies.[6] This biphasic unfolding was also observed by Grimsley et al. in a study of organophosphorus hydrolase (EC 3.1.8.1), and was attributed to the presence of a dimeric unfolded intermediate.[17] In contrast, *p*FF-F104A exhibited a single transition at (49.7 ± 0.2) °C, which was higher than both *p*FF-PTE values (by 7.7 and 1.18°C; Figure 2B, Table S1). Remarkably, after heating, *p*FF-F104A retained the single  $T_m$  of (49.2 ± 0.1) °C, thus demonstrating regaining of structure after undergoing thermal unfolding. In the absence of *p*FF, F104A demonstrated two transitions similar to *p*FF-PTE (Figure 2A), thus suggesting that fluorination was critical for stability. These data demonstrate the overall thermodynamic stability of *p*FF-F104A.

### 1.4.1 Protein design

Although methods enabling the biosynthesis of artificial proteins bearing NCAAs are abundant,[1] tools to help further improve the overall activity and stability are needed. Mutagenesis and evolutionary approaches have been employed successfully to identify variants with enhanced function; however, these rely heavily on testing

or screening several to millions of constructs.[3c, 5, 20] We demonstrate the use of computational methods to identify a fluorinated protein variant that exhibits superior heat stability and half-life. Notably, the *p*FF-F104A variant is only functional in the fluorinated form, thus validating Rossetta-based design with *p*FF. This provides another useful tool for protein design and could be employed in conjunction with the above mentioned approaches.

### 1.4.2 Future work

## References

1. Ghanem, E. & Raushel, F. M. *Detoxification of organophosphate nerve agents by bacterial phosphotriesterase* in *Toxicology and Applied Pharmacology* **207** (2005).
2. Soreq, H. & Seidman, S. *Acetylcholinesterase—new roles for an old actor*. 2001.
3. Yang, C.-Y., Renfrew, P. D., Olsen, A. J., Zhang, M., Yuvienko, C., Bonneau, R. & Montclare, J. K. Improved stability and half-life of fluorinated phosphotriesterase using Rosetta. *ChemBiochem: A European Journal of Chemical Biology* **15**, 1761–1764 (Aug. 2014).
4. Mahto, S. K., Howard, C. J., Shimko, J. C. & Ottesen, J. J. A reversible protection strategy to improve Fmoc-SPPS of peptide thioesters by the N-acylurea approach. *ChemBioChem* **12**, 2488–2494 (2011).